ELAVL1 and hepatocellular carcinoma: HuR targets include invasive and metastatic RNAs (e.g., MMP-9, MTA1, and uPA), angiogenic RNAs (e.g., VEGF-1 and HIF-1), and cell proliferative RNAs (e.g., EGF, cyclin A, cyclin B1, cyclin E, and cyclin D1), through which it can influence hepatocellular carcinoma progression [50,51].